Losartan is not a common cause of hyponatremia, and large population studies have not consistently linked it to low sodium. When hyponatremia appears during losartan therapy, it is usually mild and multifactorial, driven by an angiotensin-related sodium-wasting effect plus one or more co-contributors. The strongest risk signal belongs to thiazide diuretics and to the combination of a thiazide with an angiotensin receptor blocker, not to losartan alone.

The Mechanism: Why an ARB Can Lower Sodium at All

Losartan blocks the angiotensin II type 1 receptor. That receptor normally mediates vasoconstriction and, more importantly for sodium balance, stimulates aldosterone release from the adrenal cortex. When you block it, aldosterone falls. Aldosterone normally drives sodium reabsorption in the distal nephron in exchange for potassium and hydrogen excretion. Lower aldosterone means more sodium stays in the tubular fluid and is excreted, while potassium is retained. This is the same physiology that makes ARBs kidney-protective and potassium-sparing, and it is the same physiology that can, at the margin, nudge serum sodium down.

The effect is normally small because the kidney has redundant sodium-retaining systems. Angiotensin II also directly stimulates proximal tubule sodium reabsorption through the sodium-hydrogen exchanger, so blocking it reduces proximal reabsorption as well. The net sodium loss is usually trivial in a person with normal renal function, adequate solute intake, and an intact thirst and ADH axis. Hyponatremia emerges when that small obligate loss is layered onto a second hit.

That second hit is where the clinical action is. Thiazide diuretics cause sodium wasting plus dilutional effects and impaired free-water clearance. SSRIs and other drugs can cause SIADH. Heart failure and cirrhosis activate the renin-angiotensin-aldosterone system and ADH. Low dietary solute intake reduces the kidney's ability to excrete free water. In each case, losartan is a contributor at most, not the sole driver. Plain language version: losartan makes the kidney hold onto slightly less sodium, and that only matters when something else is already pushing sodium down.

How Common Is It? Quantified Context

Isolated ARB-associated hyponatremia is described in case reports and case series, and it is uncommon. Large cardiovascular outcome trials of losartan in hypertension and diabetic nephropathy did not flag hyponatremia as a prominent adverse effect. When it does occur, serum sodium is typically in the mild range of 130 to 134 mmol/L, often detected on routine labs and asymptomatic.

The contrast with thiazides is stark. Thiazide-associated hyponatremia is a well-recognized, relatively frequent event, especially in older women and in the first weeks of therapy. The risk rises further when a thiazide is combined with an ARB or ACE inhibitor, because the two agents act on different segments of the nephron and their sodium-wasting effects add. This is the combination that most often produces clinically relevant hyponatremia in practice.

Timing matters. Drug-induced hyponatremia from thiazides typically appears within the first two to four weeks of starting or dose escalation. ARB-attributable hyponatremia, when reported, tends to be idiosyncratic and can appear at any point, so a new low sodium months into stable losartan therapy should prompt a search for another cause first. Sodium is the most common electrolyte disorder in hospitalized patients, so the base rate of hyponatremia is high regardless of any single drug.

Who Is at Higher Risk: Edge Cases

Several patient profiles deserve closer sodium surveillance on losartan.

Older adults, especially women, with lower body weight and reduced renal reserve. People taking a thiazide diuretic, particularly a thiazide-ARB single-pill combination. Patients with heart failure, cirrhosis, or advanced chronic kidney disease, where ADH and aldosterone physiology is already distorted. Anyone on an SSRI, SNRI, carbamazepine, or other agent that can cause SIADH. People with low dietary solute intake, including heavy "tea and toast" diets or beer-potomania patterns. Patients with recent vomiting, diarrhea, or aggressive diuresis, where volume depletion drives ADH.

A counterintuitive detail worth knowing: in heart failure, losartan is often sodium-neutral or even helpful because it blunts the neurohormonal drive that causes dilutional hyponatremia. The same drug that can theoretically waste sodium can, in a different physiology, improve it. This is why the clinical context, not the drug label alone, determines the answer.

Misconceptions Worth Correcting

The first misconception is that all blood pressure drugs lower sodium equally. They do not. Thiazides, and to a lesser degree loop diuretics, are the diuretic classes most associated with hyponatremia. ARBs, ACE inhibitors, and calcium channel blockers are far less commonly implicated. Attributing a low sodium to losartan without checking the rest of the medication list is a common error.

The second misconception is that a low sodium on losartan means the drug must be stopped. Often the correct move is to identify and address the co-contributor, review fluid and solute intake, and recheck. Abruptly stopping an ARB in a patient with heart failure or diabetic kidney disease can carry its own risks.

The third misconception is that potassium and sodium move together. ARBs raise potassium and can lower sodium, so a patient on losartan with both a low sodium and a high potassium deserves a careful review rather than a reflexive dose change. The fourth is that a normal sodium on the first check rules out a drug effect. Hyponatremia can develop after weeks of stable therapy, so repeat monitoring after any new co-prescription is reasonable.

Practical Actions and Thresholds

There is no universal sodium threshold that mandates stopping losartan. The actions below are general clinical principles, not patient-specific instructions.

Check a basic metabolic panel within one to two weeks of starting losartan or increasing the dose, and again after adding a thiazide or an SSRI. Treat serum sodium below 130 mmol/L as a prompt for same-day clinical review; below 125 mmol/L as a potential emergency requiring urgent assessment. Review every medication for hyponatremia potential before blaming losartan. Assess volume status: orthostatic vitals, mucous membranes, and weight trend help separate sodium depletion from dilution. Review dietary solute and fluid intake, especially in older adults with poor appetite. Do not adjust or stop losartan without clinician guidance, particularly in heart failure or kidney disease.

A useful reconciliation: different sources cite different "action" thresholds. Many labs flag sodium below 135 mmol/L as low, clinicians often act on symptoms below 130 mmol/L, and severe hyponatremia is generally defined as below 125 mmol/L. These are not contradictions; they reflect the difference between a reference range, a clinical action point, and an emergency definition.

Comparison With Other Antihypertensives

Drug class Example Hyponatremia risk Typical mechanism
Thiazide diuretic Hydrochlorothiazide Highest among common antihypertensives Sodium wasting plus impaired free-water clearance
Loop diuretic Furosemide Moderate Sodium wasting, variable dilution
ARB Losartan Low, usually multifactorial Reduced aldosterone-mediated sodium reabsorption
ACE inhibitor Lisinopril Low Similar to ARB
Calcium channel blocker Amlodipine Very low Minimal direct sodium effect
Beta blocker Metoprolol Very low Minimal direct sodium effect

The table makes the practical point: if a patient on losartan develops hyponatremia, the thiazide in the regimen is the more likely culprit. Case reports of ARB-associated hyponatremia exist and are legitimate, but they are the exception, not the rule.

Time Course and Limitations

Phase What to expect Monitoring implication
Days 0-3 after starting losartan Minimal change in most patients Baseline labs before or shortly after start
Weeks 1-4 Highest window for thiazide-driven hyponatremia if combined Recheck sodium within 1-2 weeks
Weeks 4-12 Idiosyncratic ARB cases may appear Recheck if symptoms develop
Months on stable therapy New low sodium usually has another cause Reassess medications and comorbidities
After adding a new drug Risk can rise quickly Recheck within 1-2 weeks

The honest limitation is that the evidence base for losartan-specific hyponatremia is thin. Much of what is known comes from case reports, pharmacovigilance signals, and extrapolation from ACE inhibitor and ARB class physiology. There is no large randomized trial designed to measure losartan-attributable hyponatremia incidence. That means the answer is best framed as "uncommon and usually multifactorial" rather than "yes" or "no." Patients with symptoms such as confusion, headache, nausea, or seizures should seek urgent care regardless of the suspected cause.